Orchid Pharma's Cephalosporin Facility Passes USFDA Inspection with Minor Observations, Secures EU GMP Renewal

Orchid Pharma Ltd. has successfully navigated a recent USFDA inspection of its cephalosporin API manufacturing facility, receiving only seven minor observations. This outcome demonstrates the company's commitment to maintaining high-quality standards in its pharmaceutical operations. Simultaneously, Orchid Pharma has secured a renewal of its EU GMP certificate for the same facility, further solidifying its position in the global pharmaceutical market. These regulatory milestones are expected to bolster Orchid Pharma's ability to supply cephalosporin APIs to regulated markets, potentially driving growth in the coming quarters.

 

Source: Based on recent company filings and industry reports.